Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 5/20 | 0.40 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6230616 | 0.92 | NQO2 (0.41) | NQO2PLA2G2APOLBKMT2ACA12 | |
| SCHEMBL6233183 | 0.90 | PLA2G2A (0.42) | NQO2PLA2G2APOLBKMT2AKDM4E | |
| SCHEMBL9055771 | 0.81 | NQO2 (0.39) | NQO2PLA2G2APOLBKMT2ACA12 | |
| SCHEMBL9055766 | 0.81 | NQO2 (0.39) | NQO2PLA2G2APOLBKMT2ACA12 | |
| SCHEMBL8572170 | 0.80 | ALDH1A1 (0.41) | NQO2PLA2G2APOLBKMT2ACA12 | |
| SCHEMBL8574414 | 0.80 | ALDH1A1 (0.41) | NQO2PLA2G2AKMT2AKDM4ES1PR4 | |
| SCHEMBL6231653 | 0.79 | EGFR (0.48) | PLA2G2APOLBKMT2AKDM4EALDH1A1 | |
| SCHEMBL8573362 | 0.76 | GABRP (0.46) | NQO2KDM4EALDH1A1GAA | |
| SCHEMBL8569654 | 0.76 | POLB (0.45) | POLBKMT2ACA12CA1CA2 | |
| SCHEMBL8569839 | 0.75 | AKR1C4 (0.42) | KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1004582-B1 | Pyridazino quinoline compounds | ASTRAZENECA AB (SE) | 2005-05-18 | — | — | EP | disclosed |
| EP-0790996-B1 | PYRIDAZINOQUINOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2002-03-27 | — | — | EP | disclosed |
| US-6232313-B1 | TREATING STROKE OR EPILEPTIC CONVULSIONS ASSOCIATED WITH EXCESSIVE CALCIUM INFLUX IN THE BRAIN CAUSED BY EXCITATORY AMINO ACIDS | ZENECA LIMITED (GB) | 2001-05-15 | — | — | US | disclosed |
| US-6214826-B1 | NERVOUS SYSTEM DISORDERS | ZENECA LIMITED (GB) | 2001-04-10 | — | — | US | disclosed |
| EP-0724583-B1 | PYRIDAZINO QUINOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2000-12-13 | — | — | EP | disclosed |
| EP-1004582-A2 | Pyridazino quinoline compounds | AstraZeneca UK Limited (GB) | 2000-05-31 | — | — | EP | disclosed |
| US-5744471-A | NERVOUS SYSTEM DISORDERS | ZENECA LIMITED (GB) | 1998-04-28 | — | — | US | disclosed |
| EP-0790996-A1 | PYRIDAZINOQUINOLINE COMPOUNDS | ZENECA LIMITED (GB) | 1997-08-27 | — | — | EP | disclosed |
| EP-0724583-A1 | PYRIDAZINO QUINOLINE COMPOUNDS | ZENECA LIMITED (GB) | 1996-08-07 | — | — | EP | disclosed |
| WO-1996015127-A1 | PYRIDAZINOQUINOLINE COMPOUNDS | ZENECA LIMITED (GB) | 1996-05-23 | — | — | WO | disclosed |
| WO-1995011244-A1 | PYRIDAZINO QUINOLINE COMPOUNDS | ZENECA LIMITED (GB) | 1995-04-27 | — | — | WO | disclosed |